These results are contradict previous data from the literature suggesting that in prostatic carcinomas ANRIL overexpression was mainly accompanied by transcriptional inactivation of the p16-CDKN2A/p15-CDKN2B/p14-ARF locus via repressive action of the two polycomb complexes PRC2 and PRC1 [6]. Here, PRC1 is linked to prostate carcinoma.